Significant Contract, License and Royalty Agreements - Additional Information (Detail)
|
1 Months Ended |
12 Months Ended |
|
|
Dec. 31, 2015
USD ($)
|
Mar. 31, 2015
USD ($)
shares
|
Jul. 31, 2011
USD ($)
Product
|
Dec. 31, 2016
USD ($)
|
Dec. 31, 2015
USD ($)
|
Dec. 31, 2014
USD ($)
|
Dec. 31, 2013
USD ($)
|
Dec. 31, 2012
USD ($)
|
Apr. 30, 2015
USD ($)
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
| Additional milestone payments related to active in-license agreements |
|
|
|
$ 106,000,000
|
|
|
|
|
|
| Collaborative Arrangement [Member] |
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
| Revenue related to drug product delivered |
|
|
|
2,400,000
|
$ 6,000,000
|
$ 5,500,000
|
|
|
|
| Number of licensed products Astellas agrees to develop | Product |
|
|
1
|
|
|
|
|
|
|
| Recognized license revenue |
|
|
$ 25,000,000
|
1,500,000
|
1,800,000
|
1,600,000
|
|
|
|
| Milestone payment upon finalization of the trial design |
|
|
|
|
|
|
|
$ 10,000,000
|
|
| Additional cash payments for achievement through commercial launch |
|
|
|
|
|
|
|
$ 65,000,000
|
|
| Revenue related to contract services delivered |
|
|
|
10,100,000
|
8,700,000
|
7,800,000
|
|
|
|
| Collaborative Arrangement [Member] | Astellas In-License Agreements [Member] |
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
| Restricted stock issued, shares | shares |
|
86,121
|
|
|
|
|
|
|
|
| Potential future milestone payments |
|
$ 99,000,000
|
|
|
|
|
|
|
|
| Collaborative Arrangement [Member] | Astellas In-License Agreements [Member] | Research and development [Member] |
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
| Cash payment for license agreement |
|
$ 250,000
|
|
|
|
|
|
|
|
| IPPOX Foundation [Member] |
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
| Contractual obligation to manufacture HIV-antigen plasmid DNA |
|
|
|
|
|
|
|
|
$ 4,100,000
|
| Revenue related to drug product delivered |
$ 4,100,000
|
|
|
|
|
|
|
|
|
| City of Hope [Member] |
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
| License fees |
|
|
|
100,000
|
100,000
|
100,000
|
|
|
|
| CytRx [Member] |
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
| License fees |
|
|
|
$ 100,000
|
$ 100,000
|
$ 100,000
|
|
|
|
| CytRx [Member] | Up-front Payment [Member] |
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
| License fees |
|
|
|
|
|
|
$ 3,800,000
|
|
|